Every year, the Medicine Maker, a global publication with a focus on the people that drive the development of small and large molecule drugs as well as advanced therapies, compiles a list of pioneers and influencers advancing the knowledge frontier, driving clinical application, and fostering industry growth. The annual Medicine Maker Power List is compiled
Myocardial infarctions, commonly called heart attacks, affect thousands of people every year. Myocardial infarctions occur when a blockage in the arteries causes a decrease in blood flow to the heart. This leads to irreversible damage to the heart muscles, loss of cardiac cells, and scarring. Cell therapy seeks to regenerate lost cardiac cells with cardiac
Hereditary pulmonary alveolar proteinosis (herPAP) is a rare life-threatening disease characterized by the slow accumulation of lipoproteins in the lungs. Surfactant and other lipoproteins are typically cleared from alveoli by a specialized group of cells called alveolar macrophages that require the signaling molecule termed granulocyte macrophage colony-stimulating growth factor (GM-CSF) to maintain normal surfactant levels.
Organ transplantation remains the only treatment for patients with advanced liver injury. Globally, the limited number of donors fails to meet the demand, making it necessary to develop alternative therapies. Bone marrow-derived macrophages (BMDMs) stimulate the proliferation of hepatocyte progenitors and reduce hepatic fibrosis in mouse models of liver damage. Thus, macrophages appear a valuable
We first heard of Holoclar’s breakthrough success in 2015, when it received recommendation for approval by the European Medicines Agency. Holoclar, developed by Italian pharmaceutical company Chiesi Farmaceutici, is based on ex vivo expanded autologous human corneal epithelial cells, which contain limbal stem cells, and which repair the cornea after injury. Now, Holoclar has received another